Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

BioNexus Gene Lab Corp

BGLC ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$0.91

▼ -5.04%

Market Cap $2.69M · Vol 18

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.69M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

6.92

Momentum

Beta

N/A

vs Market

52W High

$5.65

83.87% below

52W Low

$0.90

1.85% above

Volume

Avg 713

P/B

1.11

Price-to-book

ROE

N/A

Return on equity

Free Float

53.08%

Public shares

Shariah Compliance8 STANDARDS

✗ BioNexus Gene Lab Corp (BGLC) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BGLC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-18.61%

-25.28%

-29.88%

-56.38%

YTD

-77.66%

-82.44%

-78.19%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$7.42M
Net Income	$-2,984,610.00
Revenue Growth (YoY)	-96.63%
Gross Margin	14.62%
Operating Margin	-41.74%
Net Profit Margin	-40.20%
ROE	N/A
ROA · ROIC	-30.32% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	0.99
P/B	1.11
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	2.93M

Technical Indicators

50-Day SMA	$1.35
200-Day SMA	$1.97
RSI (14)	6.92
Beta	N/A
52-Week High	$5.65
52-Week Low	$0.90

Volume Today	18
Avg Daily Volume (30D)	713
Relative Volume	0.03x
Volatility (10D)	58.49
Volatility (30D)	71.17
Free Float	53.08%

Analyst Consensus

N/A

Current Price $0.91

Mean Target N/A

52W Low$0.90 52W High$5.65

Current

Target

$0.90 $5.65

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00N70PLZ9

ISINUS0906283066

CountryMalaysia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.53% ONC BeOne Medicines AG -0.33% 068270.KS Celltrion, Inc. +1.22% MEDP Medpace Holdings, Inc. -3.77% CRL Charles River Laboratories International, Inc. -4.44%

Company Profile

BioNexus Gene Lab Corp. is a biotechnology company specializing in precision diagnostics and specialty chemical solutions. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.